\-\ Texto\\:\\ \ \(0\)\
\-\ thin\\ male\\ in\\ no\\ acute\\ distress\\.\ \(0\)\
\-\ vss\\.\ \(0\)\
\-\ chest\\ \\-\\ trace\\ bibasilar\\ crackles\\.\ \(0\)\
\-\ otherwise\\ unremarkable\\ pe\\.\ \(0\)\
\-\ pertinent\\ labs\\:\ \(0\)\
\-\ 1\\)\\ serum\\ calcium\\ \\-\\ 14\\ mg\\/dl\\.\\ \ \(0\)\
\-\ 2\\)\\ hemoglobin\\ \\-\\ 11\\ gm\\/dl\\.\ \(0\)\
\-\ 3\\)\\ hematocrit\\ \\-\\ 33\\%\ \(0\)\
\-\ 4\\)\\ ace\\ \\-\\ 72\\ micrograms\\/liter\\.\ \(0\)\
\-\ 5\\)\\ sputum\\,\\ acid\\ fast\\ stain\\ \\-\\ negative\\.\ \(0\)\
\-\ 6\\)\\ sputum\\,\\ mycobacterial\\ culture\\ \\-\\ negative\\.\ \(0\)\
\-\ steroids\\ are\\ the\\ drug\\ of\\ choice\\ for\\ the\\ treatment\\ of\\ sarcoidosis\\.\\ treatment\\ is\\ indicated\\ for\\ significant\\ pulmonary\\ functional\\ impairment\\,\\ for\\ ocular\\/myocardial\\/cns\\ disease\\.\\ most\\ therapeutic\\ regimens\\ employ\\ prednisone\\ with\\ tapered\\ dosages\\ over\\ an\\ interval\\ of\\ 6\\ months\\ or\\ more\\ until\\ a\\ response\\ is\\ observed\\.\ \(0\)\
\-\ 1\\)\\ cxr\\,\\ pa\\/lat\\ \\-\\ bilateral\\ hilar\\ prominence\\,\\ likely\\ nodal\\.\\ \ \(0\)\
\-\ 2\\)\\ gallium\\ scintigram\\ wb\\ planar\\ anterior\\ \\&\\ posterior\\ views\\,\\ 72\\ hrs\\ \\-\\ abnormal\\,\\ increased\\,\\ nodular\\-appearing\\ tracer\\ uptake\\ in\\ the\\ bilateral\\ hila\\.\\ the\\ foci\\ of\\ uptake\\ are\\ equally\\ intense\\,\\ partially\\ confluent\\,\\ and\\ of\\ greater\\ intensity\\ than\\ the\\ sternum\\ and\\ vertebral\\ column\\.\\ radiotracer\\ concentration\\ in\\ the\\ skeleton\\,\\ liver\\,\\ spleen\\,\\ and\\ gi\\ tract\\ appears\\ physiologic\\.\\ the\\ salivary\\ and\\ lacrimal\\ gland\\ uptake\\ appears\\ physiologic\\.\\ there\\ is\\ abnormal\\ bilateral\\ symmetric\\ renal\\ retention\\ \\(\\>48\\ hours\\ after\\ gallium\\ dosing\\)\\.\ \(0\)\
\-\ sarcoidosis\ \(108\)\
\-\ 1\\)\\ \\ sarcoidosis\ \(0\)\
\-\ 2\\)\\ \\ tb\ \(0\)\
\-\ 3\\)\\ \\ coccidiomycosis\ \(0\)\
\-\ 4\\)\\ \\ histoplasmosis\ \(0\)\
\-\ 5\\)\\ \\ lymphoma\ \(0\)\
\-\ 6\\)\\ \\ metastatic\\ disease\ \(0\)\
\-\ 7\\)\\ \\ eg\\ \\(langerhan\\ histiocytosis\\)\ \(0\)\
\-\ 8\\)\\ \\ silicosis\ \(0\)\
\-\ 9\\)\\ \\ berylliosis\ \(0\)\
\-\ 10\\)\\ hypersensitivity\\ pneumonitis\ \(0\)\
\-\ 58\\ year\\ old\\ male\\ with\\ a\\ 2\\ month\\ history\\ of\\ dry\\ cough\\ and\\ dyspnea\\.\\ persistent\\ hypercalcemia\\.\\ hilar\\ adenopathy\\ on\\ cxr\\.\ \(0\)\
\-\ regarding\\ the\\ gallium\\ scintigram\\ in\\ sarcoidosis\\ \\-\\ it\\ reflects\\ disease\\ activity\\.\ \(0\)\
\-\ 1\\)\\ \\'lambda\\ sign\\'\\ \\-\\ bilateral\\ symmetric\\ hilar\\ uptake\\ with\\ paratracheal\\ uptake\\ \\-\\ is\\ a\\ characteristic\\ pattern\\ of\\ uptake\\ in\\ active\\ sarcoidosis\\.\\ though\\ there\\ is\\ bilateral\\ symmetric\\ hilar\\ uptake\\,\\ there\\ is\\ no\\ classic\\ \\'lambda\\ sign\\'\\.\ \(0\)\
\-\ 2\\)\\ \\'panda\\ sign\\'\\ \\-\\ nasopharyngeal\\ uptake\\ with\\ bilateral\\ symmetric\\ parotid\\,\\ salivary\\,\\ and\\ lacrimal\\ gland\\ uptake\\ \\-\\ is\\ a\\ characteristic\\ pattern\\ of\\ uptake\\ in\\ active\\ sarcoidosis\\.\\ though\\ there\\ is\\ nasopharyngeal\\ uptake\\,\\ there\\ is\\ no\\ classic\\ \\'panda\\ sign\\'\\.\ \(0\)\
\-\ 3\\)\\ \\ in\\ this\\ case\\,\\ there\\ is\\ no\\ abnormal\\ pulmonary\\ parenchymal\\ uptake\\.\\ this\\ is\\ suggestive\\ of\\ stage\\ 1\\ disease\\ or\\ inactive\\ stage\\ 2\\ disease\\.\\ stage\\ 2\\ disease\\,\\ by\\ definition\\,\\ involves\\ the\\ parenchyma\\.\\ \\ \ \(0\)\
\-\ 4\\)\\ \\ within\\ the\\ first\\ 24\\ hours\\,\\ the\\ kidneys\\ excrete\\ \\>\\ colon\\.\\ by\\ 48\\ hours\\,\\ the\\ colon\\ excretes\\ \\>\\ kidneys\\.\\ \\ in\\ this\\ case\\,\\ at\\ 72\\ hours\\,\\ there\\ is\\ persistent\\ renal\\ gallium\\ accumulation\\ suggestive\\ of\\ renal\\ dysfunction\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ uptake\\:\\ 0\\.4192390584986771\ \(0\)\
\-\ gallium\\:\\ 0\\.26144700987318004\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.23092111586191433\ \(0\)\
\-\ hilar\\:\\ 0\\.166647886405441\ \(0\)\
\-\ symmetric\\:\\ 0\\.15574279148780862\ \(0\)\
\-\ is\\:\\ 0\\.1493110829393396\ \(0\)\
\-\ bilateral\\:\\ 0\\.14650957626938788\ \(0\)\
\-\ hours\\:\\ 0\\.1385129247191692\ \(0\)\
\-\ 72\\:\\ 0\\.1313772500595326\ \(0\)\
\-\ scintigram\\:\\ 0\\.13072350493659002\ \(0\)\
\-\ there\\:\\ 0\\.12654817065398175\ \(0\)\
\-\ sign\\:\\ 0\\.12581981569116996\ \(0\)\
\-\ disease\\:\\ 0\\.1144311364047633\ \(0\)\
\-\ nasopharyngeal\\:\\ 0\\.10945721802235933\ \(0\)\
\-\ the\\:\\ 0\\.10879033106383953\ \(0\)\
\-\ stage\\:\\ 0\\.10854560477532095\ \(0\)\
\-\ lacrimal\\:\\ 0\\.10786290952472571\ \(0\)\
\-\ salivary\\:\\ 0\\.10712185543540755\ \(0\)\
\-\ physiologic\\:\\ 0\\.10385952340714807\ \(0\)\
\-\ sputum\\:\\ 0\\.10165881749863348\ \(0\)\
\-\ in\\:\\ 0\\.09042135035328784\ \(0\)\
\-\ of\\:\\ 0\\.08891361801845195\ \(0\)\
\-\ renal\\:\\ 0\\.0848803394161414\ \(0\)\
\-\ abnormal\\:\\ 0\\.08188960550347656\ \(0\)\
\-\ though\\:\\ 0\\.07894572119801914\ \(0\)\
\-\ 48\\:\\ 0\\.07870064266861139\ \(0\)\
\-\ kidneys\\:\\ 0\\.07822151511683234\ \(0\)\
\-\ suggestive\\:\\ 0\\.07399678793641666\ \(0\)\
\-\ gland\\:\\ 0\\.07381678839183087\ \(0\)\
\-\ characteristic\\:\\ 0\\.07346277848519116\ \(0\)\
\-\ cxr\\:\\ 0\\.07269389942774457\ \(0\)\
\-\ excretes\\:\\ 0\\.07265991203028772\ \(0\)\
\-\ persistent\\:\\ 0\\.0700135278988419\ \(0\)\
\-\ employ\\:\\ 0\\.0694304249768266\ \(0\)\
\-\ dosages\\:\\ 0\\.0694304249768266\ \(0\)\
\-\ excrete\\:\\ 0\\.0694304249768266\ \(0\)\
\-\ colon\\:\\ 0\\.06918938945963647\ \(0\)\
\-\ classic\\:\\ 0\\.06796589537236386\ \(0\)\
\-\ pattern\\:\\ 0\\.06784240800821022\ \(0\)\
\-\ active\\:\\ 0\\.06747758770783785\ \(0\)\
\-\ appears\\:\\ 0\\.06654370625261036\ \(0\)\
\-\ tapered\\:\\ 0\\.06268178639898914\ \(0\)\
\-\ berylliosis\\:\\ 0\\.06268178639898914\ \(0\)\
\-\ reflects\\:\\ 0\\.06268178639898914\ \(0\)\
\-\ coccidiomycosis\\:\\ 0\\.061618222863957434\ \(0\)\
\-\ dosing\\:\\ 0\\.06068009334020031\ \(0\)\
\-\ inactive\\:\\ 0\\.06068009334020031\ \(0\)\
\-\ no\\:\\ 0\\.05909933739621858\ \(0\)\
\-\ regimens\\:\\ 0\\.05908177230086892\ \(0\)\
\-\ wb\\:\\ 0\\.05908177230086892\ \(0\)\
\-\ hila\\:\\ 0\\.0583887358104963\ \(0\)\
\-\ and\\:\\ 0\\.056331097047261615\ \(0\)\
\-\ negative\\:\\ 0\\.05625657443164398\ \(0\)\
\-\ pulmonary\\:\\ 0\\.05538903937723593\ \(0\)\
\-\ langerhan\\:\\ 0\\.055159248757035165\ \(0\)\
\-\ ace\\:\\ 0\\.054728609011179666\ \(0\)\
\-\ mycobacterial\\:\\ 0\\.054728609011179666\ \(0\)\
\-\ hrs\\:\\ 0\\.054728609011179666\ \(0\)\
\-\ sternum\\:\\ 0\\.054728609011179666\ \(0\)\
\-\ concentration\\:\\ 0\\.05432006330196472\ \(0\)\
\-\ silicosis\\:\\ 0\\.05393145476236286\ \(0\)\
\-\ parotid\\:\\ 0\\.05393145476236286\ \(0\)\
\-\ retention\\:\\ 0\\.053206874091743586\ \(0\)\
\-\ hypercalcemia\\:\\ 0\\.053206874091743586\ \(0\)\
\-\ equally\\:\\ 0\\.052867891227331154\ \(0\)\
\-\ trace\\:\\ 0\\.05254274832313715\ \(0\)\
\-\ nodal\\:\\ 0\\.05254274832313715\ \(0\)\
\-\ confluent\\:\\ 0\\.05254274832313715\ \(0\)\
\-\ hypersensitivity\\:\\ 0\\.05254274832313715\ \(0\)\
\-\ pneumonitis\\:\\ 0\\.05254274832313715\ \(0\)\
\-\ vss\\:\\ 0\\.05223035945705932\ \(0\)\
\-\ tracer\\:\\ 0\\.05223035945705932\ \(0\)\
\-\ bibasilar\\:\\ 0\\.051360598551383585\ \(0\)\
\-\ planar\\:\\ 0\\.051090576248503584\ \(0\)\
\-\ histoplasmosis\\:\\ 0\\.05057653369762714\ \(0\)\
\-\ paratracheal\\:\\ 0\\.05033144066424264\ \(0\)\
\-\ fast\\:\\ 0\\.050093664944281975\ \(0\)\
\-\ definition\\:\\ 0\\.050093664944281975\ \(0\)\
\-\ stain\\:\\ 0\\.04942017421856885\ \(0\)\
\-\ skeleton\\:\\ 0\\.04942017421856885\ \(0\)\
\-\ impairment\\:\\ 0\\.04841061017919771\ \(0\)\
\-\ eg\\:\\ 0\\.04841061017919771\ \(0\)\
\-\ column\\:\\ 0\\.04822319223563584\ \(0\)\
\-\ hemoglobin\\:\\ 0\\.04804008313453862\ \(0\)\
\-\ prominence\\:\\ 0\\.04804008313453862\ \(0\)\
\-\ prednisone\\:\\ 0\\.04786108919504245\ \(0\)\
\-\ dry\\:\\ 0\\.04786108919504245\ \(0\)\
\-\ regarding\\:\\ 0\\.047686029508578434\ \(0\)\
\-\ acid\\:\\ 0\\.047182816184525404\ \(0\)\
\-\ hematocrit\\:\\ 0\\.047021903739972004\ \(0\)\
\-\ crackles\\:\\ 0\\.04686417789082084\ \(0\)\
\-\ this\\:\\ 0\\.04683650186256422\ \(0\)\
\-\ pertinent\\:\\ 0\\.046119252649493694\ \(0\)\
\-\ therapeutic\\:\\ 0\\.045978277374553386\ \(0\)\
\-\ case\\:\\ 0\\.04565175795567854\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.04556973166533844\ \(0\)\
\-\ functional\\:\\ 0\\.04457282036111682\ \(0\)\
\-\ spleen\\:\\ 0\\.04422895854089999\ \(0\)\
\-\ dysfunction\\:\\ 0\\.044117559590704875\ \(0\)\
\-\ culture\\:\\ 0\\.044007697226817535\ \(0\)\
\-\ accumulation\\:\\ 0\\.043899329635403696\ \(0\)\
\-\ 58\\:\\ 0\\.043686919844849376\ \(0\)\
\-\ treatment\\:\\ 0\\.043285878519923895\ \(0\)\
\-\ choice\\:\\ 0\\.043081700066566406\ \(0\)\
\-\ intense\\:\\ 0\\.04288976559603256\ \(0\)\
\-\ response\\:\\ 0\\.0419096048660218\ \(0\)\
\-\ drug\\:\\ 0\\.04134333330765569\ \(0\)\
\-\ for\\:\\ 0\\.04131268998477151\ \(0\)\
\-\ interval\\:\\ 0\\.04111245061720499\ \(0\)\
\-\ calcium\\:\\ 0\\.04103695341591164\ \(0\)\
\-\ parenchymal\\:\\ 0\\.04081466284614492\ \(0\)\
\-\ serum\\:\\ 0\\.040741923572545906\ \(0\)\
\-\ male\\:\\ 0\\.040458516592566995\ \(0\)\
\-\ observed\\:\\ 0\\.04045743279138824\ \(0\)\
\-\ tb\\:\\ 0\\.04045743279138824\ \(0\)\
\-\ 33\\:\\ 0\\.03998278798828496\ \(0\)\
\-\ dyspnea\\:\\ 0\\.03998278798828496\ \(0\)\
\-\ steroids\\:\\ 0\\.03991723292602838\ \(0\)\
\-\ radiotracer\\:\\ 0\\.03966027854257143\ \(0\)\
\-\ involves\\:\\ 0\\.03953484453129685\ \(0\)\
\-\ partially\\:\\ 0\\.03899362463710783\ \(0\)\
\-\ by\\:\\ 0\\.038588383209501746\ \(0\)\
\-\ adenopathy\\:\\ 0\\.03821864901759309\ \(0\)\
\-\ gi\\:\\ 0\\.03816607526168422\ \(0\)\
\-\ tract\\:\\ 0\\.03806195750324003\ \(0\)\
\-\ until\\:\\ 0\\.037807466362450505\ \(0\)\
\-\ pe\\:\\ 0\\.03756085548340126\ \(0\)\
\-\ indicated\\:\\ 0\\.037368921012867415\ \(0\)\
\-\ foci\\:\\ 0\\.037135329635057966\ \(0\)\
\-\ parenchyma\\:\\ 0\\.036908394195915434\ \(0\)\
\-\ distress\\:\\ 0\\.03660117007341098\ \(0\)\
\-\ views\\:\\ 0\\.03586162833691986\ \(0\)\
\-\ with\\:\\ 0\\.035586697553612406\ \(0\)\
\-\ thin\\:\\ 0\\.035367227954078595\ \(0\)\
\-\ vertebral\\:\\ 0\\.03469573069480101\ \(0\)\
\-\ are\\:\\ 0\\.03448077400770978\ \(0\)\
\-\ 11\\:\\ 0\\.0340139999481317\ \(0\)\
\-\ 14\\:\\ 0\\.03392120400410511\ \(0\)\
\-\ cough\\:\\ 0\\.03392120400410511\ \(0\)\
\-\ greater\\:\\ 0\\.033472780053942684\ \(0\)\
\-\ activity\\:\\ 0\\.03335734477107027\ \(0\)\
\-\ otherwise\\:\\ 0\\.0323874445825253\ \(0\)\
\-\ intensity\\:\\ 0\\.032261614238799634\ \(0\)\
\-\ 24\\:\\ 0\\.032211833482367155\ \(0\)\
\-\ or\\:\\ 0\\.031611818172400864\ \(0\)\
\-\ labs\\:\\ 0\\.03147754938504318\ \(0\)\
\-\ liver\\:\\ 0\\.03134292823497249\ \(0\)\
\-\ first\\:\\ 0\\.030661023675275175\ \(0\)\
\-\ unremarkable\\:\\ 0\\.030459369990476562\ \(0\)\
\-\ month\\:\\ 0\\.027638428646230374\ \(0\)\
\-\ likely\\:\\ 0\\.02715062959554322\ \(0\)\
\-\ lymphoma\\:\\ 0\\.027059153174605666\ \(0\)\
\-\ 10\\:\\ 0\\.02656788142368273\ \(0\)\
\-\ months\\:\\ 0\\.02644664780304739\ \(0\)\
\-\ significant\\:\\ 0\\.026232971632793815\ \(0\)\
\-\ than\\:\\ 0\\.025755616825741307\ \(0\)\
\-\ anterior\\:\\ 0\\.025368058994550923\ \(0\)\
\-\ over\\:\\ 0\\.02526366831150542\ \(0\)\
\-\ more\\:\\ 0\\.02494848775395312\ \(0\)\
\-\ metastatic\\:\\ 0\\.024918638018448278\ \(0\)\
\-\ acute\\:\\ 0\\.024578413839437895\ \(0\)\
\-\ increased\\:\\ 0\\.024568903515798553\ \(0\)\
\-\ chest\\:\\ 0\\.023982715753982448\ \(0\)\
\-\ most\\:\\ 0\\.023645572739685997\ \(0\)\
\-\ posterior\\:\\ 0\\.02349465442264409\ \(0\)\
\-\ it\\:\\ 0\\.02325736727162096\ \(0\)\
\-\ after\\:\\ 0\\.022041098232080093\ \(0\)\
\-\ within\\:\\ 0\\.020925803219882244\ \(0\)\
\-\ an\\:\\ 0\\.017374061361044628\ \(0\)\
\-\ history\\:\\ 0\\.017358670254609666\ \(0\)\
\-\ at\\:\\ 0\\.0171612461601066\ \(0\)\
\-\ year\\:\\ 0\\.014002067590564072\ \(0\)\
\-\ on\\:\\ 0\\.013722047105820704\ \(0\)\
\-\ old\\:\\ 0\\.013446831822922334\ \(0\)\
